Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Ironwood Pharma (IRWD) Tops Q1 EPS by 3c, Revenues Miss; Offers FY21 Revenues Guidance Above Consensus
May 6, 2021 7:49 AM EDTIronwood Pharma (NASDAQ: IRWD) reported Q1 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $88.85 million versus the consensus estimate of $95.2 million.
We are off to a solid start to the year, as LINZESS continued the strong... More
